Published in Regul Toxicol Pharmacol on August 09, 2006
Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities. J Expo Sci Environ Epidemiol (2008) 1.97
Human health effects of tetrachloroethylene: key findings and scientific issues. Environ Health Perspect (2014) 0.90
Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation. J Toxicol (2012) 0.90
Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environ Health Perspect (2008) 0.89
Application of physiologically based pharmacokinetic models in chemical risk assessment. J Toxicol (2012) 0.78
Weighted Markov chains for forecasting and analysis in Incidence of infectious diseases in jiangsu Province, China. J Biomed Res (2010) 0.77
Development of a human Physiologically Based Pharmacokinetic (PBPK) Toolkit for environmental pollutants. Int J Mol Sci (2011) 0.77
Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults. PLoS One (2016) 0.75
Physiological fidelity or model parsimony? The relative performance of reverse-toxicokinetic modeling approaches. BMC Syst Biol (2017) 0.75
In vitro-in silico based analysis of the dose-dependent in vivo estrogenicity of the soy phytoestrogen genistein in humans. Br J Pharmacol (2017) 0.75
Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal (2008) 5.57
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol (2009) 2.78
Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes (2007) 2.59
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci (2011) 2.03
A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci (2012) 1.81
ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol (2009) 1.63
Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Anal (2007) 1.61
Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat. Toxicol Sci (2008) 1.51
Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect (2010) 1.47
Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol (2012) 1.46
Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Crit Rev Toxicol (2004) 1.45
Long-term environmental exposure to perchlorate through drinking water and thyroid function during pregnancy and the neonatal period. Thyroid (2005) 1.45
Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Toxicol Sci (2003) 1.44
Application of biologically based computer modeling to simple or complex mixtures. Environ Health Perspect (2002) 1.42
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol Sci (2005) 1.35
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. Toxicology (2006) 1.34
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci (2010) 1.30
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology (2010) 1.28
A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol (2009) 1.25
A deterministic map of Waddington's epigenetic landscape for cell fate specification. BMC Syst Biol (2011) 1.21
Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J Expo Sci Environ Epidemiol (2006) 1.19
Ultrasensitive response motifs: basic amplifiers in molecular signalling networks. Open Biol (2013) 1.16
Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. Toxicol Appl Pharmacol (2009) 1.15
Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect (2013) 1.14
Single cell analysis of switch-like induction of CYP1A1 in liver cell lines. Toxicol Sci (2004) 1.13
Evidence of a "clear and consistent threshold" for bladder and liver cancer in the large ED01 carcinogenicity study. Toxicol Sci (2003) 1.12
The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch Toxicol (2007) 1.11
Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes (2012) 1.10
Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci (2013) 1.10
New directions in toxicity testing. Annu Rev Public Health (2011) 1.09
Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One (2011) 1.09
Induction of CYP1A1 in primary rat hepatocytes by 3,3',4,4',5-pentachlorobiphenyl: evidence for a switch circuit element. Toxicol Sci (2004) 1.08
Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol Appl Pharmacol (2004) 1.08
Long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes. Environ Health Perspect (2010) 1.07
Dose response relationship in anti-stress gene regulatory networks. PLoS Comput Biol (2006) 1.07
Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci (2007) 1.07
Quantitative interpretation of human biomonitoring data. Toxicol Appl Pharmacol (2008) 1.07
Linear low-dose extrapolation for noncancer heath effects is the exception, not the rule. Crit Rev Toxicol (2011) 1.07
Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein β during adipogenesis. Free Radic Biol Med (2011) 1.07
t4 workshop report: Pathways of Toxicity. ALTEX (2013) 1.06
Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ Sci Technol (2005) 1.04
Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci (2010) 1.03
Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci (2013) 1.03
Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J Toxicol Environ Health A (2006) 1.03
Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology (2010) 1.03
Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. Toxicol Appl Pharmacol (2007) 1.02
Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. Biochem Biophys Res Commun (2011) 1.02
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn (2012) 1.02
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A (2013) 1.00
A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci (2007) 1.00
Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J Mol Endocrinol (2007) 0.99
Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci (2010) 0.99
Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul Toxicol Pharmacol (2006) 0.98
An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther (2012) 0.98
Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci (2013) 0.98
In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ Health Perspect (2002) 0.98
Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology (2006) 0.98
A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. ALTEX (2010) 0.96
Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regul Toxicol Pharmacol (2008) 0.96
Can case study approaches speed implementation of the NRC report: "toxicity testing in the 21st century: a vision and a strategy?". ALTEX (2011) 0.95
Dose-dependent transitions in mechanisms of toxicity. Toxicol Appl Pharmacol (2004) 0.95
Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett (2007) 0.95
Progestin receptor expression in the developing rat brain depends upon activation of estrogen receptor alpha and not estrogen receptor beta. Brain Res (2006) 0.94
Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. J Toxicol Environ Health A (2003) 0.94
Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound. Toxicol Sci (2010) 0.93
Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol (2012) 0.93
Evidence that atrazine and diaminochlorotriazine inhibit the estrogen/progesterone induced surge of luteinizing hormone in female Sprague-Dawley rats without changing estrogen receptor action. Toxicol Sci (2004) 0.93
The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX (2012) 0.93
Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. Regul Toxicol Pharmacol (2007) 0.93
Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci (2011) 0.92
Detection and localization of an estrogen receptor beta splice variant protein (ERbeta2) in the adult female rat forebrain and midbrain regions. J Comp Neurol (2007) 0.92
Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res (2012) 0.92
Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. Inhal Toxicol (2008) 0.91
Making sense of human biomonitoring data: findings and recommendations of a workshop. J Expo Sci Environ Epidemiol (2007) 0.91
Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol In Vitro (2009) 0.91
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol (2003) 0.90
Physiologically based pharmacokinetic modeling of arsenic in the mouse. J Toxicol Environ Health A (2004) 0.90
Regional induction of CYP1A1 in rat liver following treatment with mixtures of PCB 126 and PCB 153. Toxicol Pathol (2004) 0.90
Cross-regulations among NRFs and KEAP1 and effects of their silencing on arsenic-induced antioxidant response and cytotoxicity in human keratinocytes. Environ Health Perspect (2012) 0.90
Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol (2007) 0.89